LEVETIRACETAM 1000mg

Levetiracetam Crescent is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.

Levetiracetam Crescent is indicated as adjunctive therapy:

• in the treatment of partial onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
• in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Pharmacotherapeutic group: antiepileptics

Levetiracetam induces seizure protection in a broad range of partial and primary generalized seizures.

Please refer to the instructions on the prescription established by your medical doctor.

Levetiracetam may be taken with or without food.

Partial onset seizures
The recommended dosing for monotherapy (from 16 years of age) and adjunctive therapy is the same as outlined below.

All indications

• Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more. 

The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. However, a lower initial dose of 250 mg twice daily may be given based on physician assessment of seizure reduction versus potential side effects. This can be increased to 500 mg twice daily after two weeks. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 250 mg or 500 mg twice daily increases or decreases every two to four weeks.

• Adolescents (12 to 17 years) weighing below 50 kg and children from 1 month of age. 

The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to weight, age and dose. 

• Elderly (65 years and older)

Adjustment of the dose is recommended in elderly patients with compromised renal function.